Teduglutide
GLP-2 analog for short bowel syndrome.
What it is
Teduglutide (Gattex, Revestive) is a synthetic GLP-2 receptor agonist FDA-approved in 2012 for adults and pediatric patients with short bowel syndrome who are dependent on parenteral nutrition.
Mechanism of action
GLP-2 receptor activation in the gut promotes intestinal mucosal growth, increases nutrient absorption, and supports intestinal adaptation following bowel resection. The clinical goal is reduction in dependence on parenteral nutrition.
Approved indications
Short bowel syndrome with dependence on parenteral nutrition.
Why this is out of scope at The Tide
Specialty gastroenterology medication for a complex GI condition appropriately managed by gastroenterology with expertise in short bowel syndrome and intestinal failure. The Tide does not provide gastroenterology services for complex intestinal conditions.
Where to learn more
Gastroenterology, particularly programs specialized in intestinal failure and short bowel syndrome.